69O Six-year survival outcomes with dostarlimab monotherapy in patients (pts) with mismatch repair-deficient/microsatellite-high (dMMR/MSI-H) endometrial cancer (EC) in the GARNET trial

The GARNET trial is the largest trial of an anti-PD-1 monotherapy, dostarlimab, in patients with dMMR/MSI-H advanced/recurrent (A/R) EC after platinum-based chemotherapy and supported global approvals in this setting. Previously published results provided robust evidence of clinical benefit and demonstrated durable antitumor activity with an acceptable safety profile. Here we report updated efficacy and safety at 6y follow-up accompanied by a conditional survival analysis to provide prognostic insights into long-term survival potential.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-07-01
DOI
https://doi.org/10.1016/j.esmoop.2026.108095
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

69O Six-year survival outcomes with dostarlimab monotherapy in patients (pts) with mismatch repair-deficient/microsatellite-high (dMMR/MSI-H) endometrial cancer (EC) in the GARNET trial

R. Miller, L. Gilbert, C Reade, C. Mathews et al.
ESMO Open
Endometrial and Cervical Cancer Treatments
article

69O Six-year survival outcomes with dostarlimab monotherapy in patients (pts) with mismatch repair-deficient/microsatellite-high (dMMR/MSI-H) endometrial cancer (EC) in the GARNET trial

R. Miller, L. Gilbert, C Reade, C. Mathews, S. Banerjee, S. Ghamande, C. Abdeddaim, R. Sabatier, J. Brown, C.A. Leath Iii, V. Samouelian, M.P. Barretina Ginesta, H.K.C. Tang, A. Tinker, S.L. Ellard, A. Oaknin, K. Yablonski, G. Vlahovic, B. Pothuri, B. Patel
article en

Abstract

The GARNET trial is the largest trial of an anti-PD-1 monotherapy, dostarlimab, in patients with dMMR/MSI-H advanced/recurrent (A/R) EC after platinum-based chemotherapy and supported global approvals in this setting. Previously published results provided robust evidence of clinical benefit and demonstrated durable antitumor activity with an acceptable safety profile. Here we report updated efficacy and safety at 6y follow-up accompanied by a conditional survival analysis to provide prognostic insights into long-term survival potential.

ESMO OpenVol. 11
Gynecologic Oncology Group (US), BC Cancer Agency (CA), Centre National de la Recherche Scientifique (FR), St Bartholomew's Hospital (GB), Royal Marsden NHS Foundation Trust (GB), University of British Columbia (CA), Inserm (FR), Barts Health NHS Trust (GB), Kelowna General Hospital (CA), McMaster University Medical Centre (CA), Cancer Research UK (GB), McGill University Health Centre (CA), University of Alabama at Birmingham (US), Augusta University Health (US), Levine Cancer Institute (US), Hospital Universitario Puerta de Hierro Majadahonda (ES), Association for Cancer Surgery (GB), Institut d'Investigació Biomèdica de Girona (ES), GlaxoSmithKline (United States) (US), Centre Oscar Lambret (FR), Women & Infants Hospital of Rhode Island (US), Centre Hospitalier de l’Université de Montréal (CA), Centre de Recherche en Cancérologie de Marseille (FR), TE Laboratories (Ireland) (IE), University College London (GB), McMaster University (CA)
Openalex Percentile: Top 6%
Endometrial and Cervical Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.